Large-scale testing (Phase 3)Ended earlyNCT04636814
What this trial is testing
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
Who this might be right for
Chronic Obstructive Pulmonary Disease
Chiesi Farmaceutici S.p.A. 3,973